Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093935 | 0.77 | TSHR (0.30) | TSHR | |
| SCHEMBL4863459 | 0.72 | — | — | |
| SCHEMBL465304 | 0.71 | TSHR (0.39) | TSHR | |
| SCHEMBL465382 | 0.71 | TSHR (0.39) | TSHR | |
| SCHEMBL2387687 | 0.69 | MEN1 (0.35) | — | |
| SCHEMBL28399026 | 0.69 | TSHR (0.37) | TSHR | |
| SCHEMBL1245010 | 0.68 | — | — | |
| SCHEMBL7861585 | 0.67 | TSHR (0.35) | TSHR | |
| SCHEMBL465474 | 0.67 | TSHR (0.35) | TSHR | |
| SCHEMBL8948437 | 0.67 | FFAR3 (0.36) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483271-B1 | HETEROCYCLIC AMIDE DERIVATIVES HAVING GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-11-22 | — | — | EP | disclosed |
| US-7138415-B2 | Indolamid derivatives which possess glycogenphosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2006-11-21 | — | — | US | disclosed |
| US-7122567-B2 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2006-10-17 | — | — | US | disclosed |
| US-20050131052-A1 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| US-20050107362-A1 | Indolamid derivatives which possess glycogenphosphorylase inhibitory activity | ASTRA ZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| EP-1483240-A1 | INDOLAMID DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| EP-1483271-A1 | HETEROCYCLIC AMIDE DERIVATIVES HAVING GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | Astrazeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074531-A1 | HETEROCYCLIC AMIDE DERIVATIVES HAVING GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003074484-A1 | INDOLAMID DERIVATIVES WHICH POSSESS GLYCOGENPHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107362-A1 | Indolamid derivatives which possess glycogenphosphorylase inhibitory activity | PYGL, PYGM, PYGB | TSHR 509/4885 |
| US-20050131052-A1 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity | PYGL, GYS1, CBR3 | TSHR 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.